Complement activation correlates with liver necrosis and fibrosis in chronic 
hepatitis C

Vasel, Matthäus; Rutz, Renate; Bersch, Claus; Feick, Peter; Singer, Manfred V.; Kirschfink, Michael; Nakchbandi, Inaam A.

doi:10.1016/j.clim.2013.11.014

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Complement activation correlates with liver necrosis and fibrosis in chronic hepatitis C

MPS-Authors

/persons/resource/persons78823

Vasel, Matthäus
Nakchbandi, Inaam / Translational Medicine, Max Planck Institute of Biochemistry, Max Planck Society;

/persons/resource/persons78436

Nakchbandi, Inaam A.
Nakchbandi, Inaam / Translational Medicine, Max Planck Institute of Biochemistry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Vasel, M., Rutz, R., Bersch, C., Feick, P., Singer, M. V., Kirschfink, M., et al. (2014). Complement activation correlates with liver necrosis and fibrosis in chronic hepatitis C. CLINICAL IMMUNOLOGY, 150(2), 149-156. doi:10.1016/j.clim.2013.11.014.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0018-F00B-D

Abstract

Chronic hepatitis C viral infection modulates complement. The aim of this study was to determine whether complement analysis predicts liver inflammation and fibrosis in patients with chronic hepatitis C. 50 chronic hepatitis C patients who underwent a liver biopsy were compared to 50 healthy controls and 35 patients with various liver diseases. Total plasma complement activity (CH50) in plasma was diminished in hepatitis C patients suggesting complement activation. This decrease correlated with increased necrosis (r = -0.24, p < 0.05), and patients with levels below the normal range had a higher METAVIR activity score reflecting enhanced inflammation. SC5b-9, a marker of complement activation, correlated with inflammation (r = 0.40, p < 0.05), activity (r = 0.42, p < 0.05), and fibrosis scores (r = 0.49, p < 0.05). Finally, the prevalence of C1q auto-antibodies was higher in hepatitis C patients, and their presence was associated with increased inflammation and seemed to affect fibrosis. We conclude that complement-induced liver inflammation contributes to fibrosis in patients with chronic hepatitis C. (C) 2013 Elsevier Inc. All rights reserved.